Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Tasly Pharma Planning $1 Billion IPO in Hong Kong for Biologics Operations

publication date: Mar 5, 2018

Tianjin Tasly Pharma is in talks to IPO its biopharma division in Hong Kong later this year with the goal of raising $1 billion. If it happens, the IPO will probably be Hong Kong's largest biopharma IPO this year. Tasly, known for its TCM offerings, has been actively using M&A to expand into biologics. It has also invested in C-Bridge Capital's funds and sometimes adds, independently, to C-Bridge deals. One year ago, C-Bridge and Tasly joined to invest $150 million in two China biotechs, merging them as part of the transaction. More details....

Stock Symbol: (SHA: 600535)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.